| |
MEDIA INQUIRIES
Mike Beyer
Sam Brown Inc.
Phone:
773-463-4211
beyer@sambrown.com
|
|
January 5, 2012
Yaupon Changes Name to Ceptaris
Therapeutics, Inc.
MALVERN, PA (January 5, 2012) – Yaupon
Therapeutics, Inc., a privately held specialty pharmaceutical
company, announced today it has changed its name to Ceptaris
Therapeutics, Inc., effective immediately. The new name is
intended to reflect the recent changes in management and the
Company’s ongoing transformation into a commercial organization.
Ceptaris Therapeutics’ lead drug candidate, mechlorethamine gel
is currently undergoing review by the U.S. Food and Drug
Administration (FDA) for the treatment of early stage (stages I-IIA)
mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL).
“With our first investigational drug under
review by the FDA, the Company is planning for entry into a
commercial phase for the first time,” said Ceptaris Chairman of
the Board and CEO Steve Tullman. “We have created a new name to
reflect this evolution in our Company’s growth and development.”
The FDA previously granted Orphan Drug Status
to this investigational drug. The new drug application (NDA) for
Ceptaris' mechlorethamine gel was filed in July 2011.
In mid-2011, Steve Tullman was named Chairman
of the Board and CEO and established a new management team that
included leadership who previously worked with him at Ception
Therapeutics, which was acquired by Cephalon, Inc. in April
2010.
About Ceptaris Therapeutics
Ceptaris Therapeutics, Inc. is a privately
held, specialty pharmaceutical company that is developing a
proprietary gel formulation of mechlorethamine hydrochloride for
the treatment of early stage (stages I-IIA) mycosis fungoides, a
type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris'
investigational drug would be the first topical mechlorethamine
gel widely available to relieve the signs and symptoms of this
rare cancer. Please visit www.ceptaris.com for more information.
# # #
|
|
